Kissei Pharmaceutical Co ((KSPHF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Kissei Pharmaceutical Co. is conducting a Phase III clinical study titled ‘Phase III Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration.’ The study aims to evaluate the efficacy and safety of the drug KPS-0373 in treating patients with spinocerebellar degeneration, a progressive condition affecting coordination and balance. This study is significant as it could lead to a new treatment option for this debilitating disease.
The intervention being tested is KPS-0373, an experimental drug administered orally once daily. The purpose of KPS-0373 is to provide therapeutic benefits to patients suffering from spinocerebellar degeneration.
The study is designed as a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Participants are randomly assigned to either the KPS-0373 group or a placebo group, with both participants and researchers unaware of group assignments to ensure unbiased results. The primary goal is to assess the treatment’s effectiveness.
The study began in July 2025 and is currently recruiting participants. It includes a 4-week screening period, a 24-week treatment period, and a 4-week follow-up period. The last update was submitted on June 25, 2025, marking the study’s initial public disclosure.
This clinical study update could positively influence Kissei Pharmaceutical’s stock performance by boosting investor confidence in the company’s research and development capabilities. The potential success of KPS-0373 may position Kissei as a leader in the treatment of spinocerebellar degeneration, impacting the competitive landscape.
The study is ongoing, and further details are available on the ClinicalTrials portal.